Innate Pharma Overview
Latest PEG ratio for Innate Pharma: -28.86 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-28.86
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
As of the most recent data, IPHA shows a PEG ratio of -28.86. That is below the Healthcare sector average of 2.56. Scroll down for historical charts and peer comparison views.
The Healthcare sector average PEG ratio is about 2.56. Innate Pharma is at -28.86, which is lower that average. That is roughly 1227.5% below the sector mean. Use the comparison chart on this page to see how IPHA stacks up against individual peers as well.
Investors watch IPHA's PEG ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Innate Pharma's latest reading is -28.86. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this peg ratio page, Stockcircle has Innate Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect PEG ratio (currently -28.86) with ownership activity and broader fundamentals.
The Healthcare average PEG ratio is about 2.56, while IPHA is at -28.86. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
